Literature DB >> 50191

An objective method for measuring dyskinetic movements in tardive dyskinesia.

D Denney, D Casey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 50191      PMCID: PMC8332547          DOI: 10.1016/0013-4694(75)90166-2

Source DB:  PubMed          Journal:  Electroencephalogr Clin Neurophysiol        ISSN: 0013-4694


× No keyword cloud information.
  8 in total

1.  Assessment of tardive dyskinesia by means of digital image processing.

Authors:  W F Gattaz; C Büchel
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

2.  Quantification of random body movements by a Doppler radar device.

Authors:  B Kemp; J M Franzen; O J Buruma; R A Roos
Journal:  Med Biol Eng Comput       Date:  1982-09       Impact factor: 2.602

Review 3.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

4.  Digital movement analysis, a new objective method of measuring tardive dyskinesia and drug-induced parkinsonian tremor: acceptability, reliability and validity.

Authors:  F M Nilsson; B L Hansen; C Buchel; W F Gattaz; J Gerlach
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

5.  Oral tardive dyskinesia: validation of a measuring device using digital image processing.

Authors:  C Büchel; J de Leon; G M Simpson; W F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

6.  [Deanol in tardive dyskinesia: a double-blind study (author's transl)].

Authors:  S Bockenheimer; G Lucius
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1976-09-17

7.  Pharmacological characterization of tardive dyskinesia.

Authors:  D E Casey; D Denney
Journal:  Psychopharmacology (Berl)       Date:  1977-08-31       Impact factor: 4.530

8.  Neuroleptic-induced movement disorders in a naturalistic schizophrenia population: diagnostic value of actometric movement patterns.

Authors:  Sven Janno; Matti M Holi; Katinka Tuisku; Kristian Wahlbeck
Journal:  BMC Neurol       Date:  2008-04-18       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.